While progress has been made toward affordable insulin in the U.S. — including through grants from Helmsley’s Type 1 Diabetes Program to organizations like Civica — there’s a critical need for affordable, quality insulin access globally.

In an opinion piece for STAT News, Trustee David Panzirer outlines what can be done, and how Helmsley-supported projects like PEN-Plus are helping make it happen: https://www.statnews.com/2023/10/24/insulin-prices-us-who-global-affordability/